TNF in the era of immune checkpoint inhibitors: friend or foe?

Adverse Effects of Low-Dose Methotrexate

(2020) Daniel H. Solomon et al.   ANNALS OF INTERNAL MEDICINE

Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry

(2020) Rik J. Verheijden et al.   CLINICAL CANCER RESEARCH

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

(2020) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo

(2020) Alexander M. M. Eggermont et al.   JAMA Oncology

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity

(2020) Laura Strauss et al.   Science Immunology

Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis

(2020) Xiaoxiang Zhou et al.   BMC Medicine

Checkpoint Inhibitor–Associated Arthritis

(2020) Nilasha Ghosh et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

Autoimmune complications of immunotherapy: pathophysiology and management

(2020) Karmela K Chan et al.   BMJ-British Medical Journal

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

(2020) Adrienne M. Luoma et al.   CELL

Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy

(2020) William Murray-Brown et al.   Journal for ImmunoTherapy of Cancer

Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors – a Nordic cohort study

(2020) Karin Hellgren et al.   RHEUMATOLOGY

A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors

(2019) Patrick Arnaud-Coffin et al.   INTERNATIONAL JOURNAL OF CANCER

Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor–induced inflammatory arthritis

(2019) Janet Roberts et al.   CLINICAL RHEUMATOLOGY

TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer

(2019) Yujia Zheng et al.   Journal of Translational Medicine

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

(2019) Elisabeth Perez-Ruiz et al.   NATURE

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma

(2019) Candice Lesage et al.   JOURNAL OF IMMUNOTHERAPY

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

(2019) Tawnie J Braaten et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling

(2019) Pim J Koelink et al.   GUT

Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis

(2019) Jiang-lin Wang et al.   CLINICAL RHEUMATOLOGY

Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors

(2018) Timothy Beukelman et al.   ANNALS OF THE RHEUMATIC DISEASES

High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma

(2018) Alexander T. Faje et al.   CANCER

Non-conventional Inhibitory CD4 + Foxp3 − PD-1 hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity

(2018) Roberta Zappasodi et al.   CANCER CELL

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

(2018) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen

(2018) Laura C. Cappelli et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion

(2018) Flávia Castro et al.   Frontiers in Immunology

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson

(2018) Yinghong Wang et al.   Journal for ImmunoTherapy of Cancer

Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis

(2018) Pauline Raaschou et al.   ANNALS OF INTERNAL MEDICINE

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

(2018) Kathryn C. Arbour et al.   JOURNAL OF CLINICAL ONCOLOGY

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome

(2018) H Torrey et al.   LEUKEMIA

Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease

(2017) Jeffrey S. Hyams et al.   GASTROENTEROLOGY

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

(2017) Magali Lemaitre et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers

(2017) Maïté de La Forest Divonne et al.   JOINT BONE SPINE

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

(2017) Mario Sznol et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma

(2017) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs

(2017) Heather Torrey et al.   Science Signaling

Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis

(2017) José Ramón Maneiro et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Arthritis after cancer immunotherapy: symptom duration and treatment response

(2017) Melanie H. Smith et al.   ARTHRITIS CARE & RESEARCH

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma

(2017) Florie Bertrand et al.   Nature Communications

Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs

(2017) Heather Torrey et al.   Science Signaling

Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased?

(2017) K. Hellgren et al.   Arthritis & Rheumatology

Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data

(2017) Seung Min Jung et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer

(2017) Alexandre Ivagnès et al.   OncoImmunology

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers

(2016) Louise K Mercer et al.   ANNALS OF THE RHEUMATIC DISEASES

Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers

(2016) Karin Hellgren et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

(2016) Louise K Mercer et al.   ANNALS OF THE RHEUMATIC DISEASES

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

(2016) L. Marthey et al.   Journal of Crohns & Colitis

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

Suppressive activity of human regulatory T cells is maintained in the presence of TNF

(2016) Bruno Zaragoza et al.   NATURE MEDICINE

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis

(2016) Lucía Silva-Fernández et al.   RHEUMATOLOGY

Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer

(2016) Frank I. Scott et al.   JAMA Dermatology

TNFR2 expression by CD4 effector T cells is required to induce full-fledged experimental colitis

(2016) Xin Chen et al.   Scientific Reports

Blocking Tumor Necrosis Factor   Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma

(2015) F. Bertrand et al.   CANCER RESEARCH

Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8+ T Cells in Mice With Colitis

(2015) Shivesh Punit et al.   GASTROENTEROLOGY

Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis

(2015) Hansje-Eva Teulings et al.   JOURNAL OF CLINICAL ONCOLOGY

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

(2015) Troy Z. Horvat et al.   JOURNAL OF CLINICAL ONCOLOGY

TNF biology, pathogenic mechanisms and emerging therapeutic strategies

(2015) George D. Kalliolias et al.   Nature Reviews Rheumatology

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neutralization of Tumor Necrosis Factor Bioactivity Ameliorates Urethane-Induced Pulmonary Oncogenesis in Mice

(2015) Sophia P. Karabela et al.   NEOPLASIA

Association between Tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis

(2014) Liping Ma et al.   Diagnostic Pathology

Anti-TNF therapy: past, present and future

(2014) C. Monaco et al.   INTERNATIONAL IMMUNOLOGY

Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease

(2014) Nynne Nyboe Andersen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cutting Edge: Expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: Applicability to Tumor-Infiltrating T Regulatory Cells

(2014) X. Chen et al.   JOURNAL OF IMMUNOLOGY

Dendritic Cell Maturation and Survival Are Differentially Regulated by TNFR1 and TNFR2

(2014) Nicola J. Maney et al.   JOURNAL OF IMMUNOLOGY

Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment

(2014) Theerawut Chanmee et al.   Cancers

Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis

(2013) Martin Chopra et al.   CARCINOGENESIS

Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment

(2013) Chindu Govindaraj et al.   CLINICAL IMMUNOLOGY

Tumor Necrosis Factor-α Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic Inflammation

(2013) Moshe Sade-Feldman et al.   IMMUNITY

Tumour necrosis factor and cancer

(2013) John P Waters et al.   JOURNAL OF PATHOLOGY

Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies

(2013) C. Pouplard et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Lymphoma development in patients with autoimmune and inflammatory disorders – What are the driving forces?

(2013) Eva Baecklund et al.   SEMINARS IN CANCER BIOLOGY

Activating natural cytotoxicity receptors of natural killer cells in cancer and infection

(2013) Joachim Koch et al.   TRENDS IN IMMUNOLOGY

TNF-α-308polymorphism and risk of digestive system cancers: A meta-analysis

(2013) Xu-Feng Guo   WORLD JOURNAL OF GASTROENTEROLOGY

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden

(2013) P. Raaschou et al.   BMJ-British Medical Journal

Expanding Roles for CD4 T Cells and Their Subpopulations in Tumor Immunity and Therapy

(2013) Mark J. Dobrzanski   Frontiers in Oncology

A Pooled Analysis of Infections, Malignancy and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease

(2012) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study

(2012) Parakkal Deepak et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases

(2012) Kevin Haynes et al.   ARTHRITIS AND RHEUMATISM

CCR2-Dependent Recruitment of Macrophages by Tumor-Educated Mesenchymal Stromal Cells Promotes Tumor Development and Is Mimicked by TNFα

(2012) Guangwen Ren et al.   Cell Stem Cell

T helper type 17 cells contribute to anti-tumour immunity and promote the recruitment of T helper type 1 cells to the tumour

(2012) Sarah Nuñez et al.   IMMUNOLOGY

Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy

(2012) Maria A. Lopez-Olivo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

TNF signaling drives myeloid-derived suppressor cell accumulation

(2012) Xueqiang Zhao et al.   JOURNAL OF CLINICAL INVESTIGATION

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: A review of their methodologies and results

(2011) D. H. Solomon et al.   ARTHRITIS AND RHEUMATISM

Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): Long-term followup of a multicenter longitudinal cohort

(2011) Francisco Silva et al.   ARTHRITIS AND RHEUMATISM

Natural but Not Inducible Regulatory T Cells Require TNF-  Signaling for In Vivo Function

(2011) W. J. Housley et al.   JOURNAL OF IMMUNOLOGY

The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials

(2011) Erica D. Dommasch et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tumor necrosis factor α blockers and malignancy in children: Forty-eight cases reported to the food and drug administration

(2010) Peter Diak et al.   ARTHRITIS AND RHEUMATISM

Molecular and histological evaluation of tumor necrosis factor-alpha expression in Helicobacter pylori-mediated gastric carcinogenesis

(2010) Cinghu Senthilkumar et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Can TNF-α boost regulatory T cells?

(2010) Angelina M. Bilate et al.   JOURNAL OF CLINICAL INVESTIGATION

Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs

(2010) Yenkel Grinberg-Bleyer et al.   JOURNAL OF CLINICAL INVESTIGATION

Expression of Costimulatory TNFR2 Induces Resistance of CD4+FoxP3- Conventional T Cells to Suppression by CD4+FoxP3+ Regulatory T Cells

(2010) X. Chen et al.   JOURNAL OF IMMUNOLOGY

Action of Bacterial Polysaccharide on Tumors. II. Damage of Sarcoma 37 by Serum of Mice Treated with Serratia Marcescens Polysaccharide, and Induced Tolerance

(2010) W. EDWARD O'MALLEY et al.   NUTRITION REVIEWS

Protein Kinase C-  Mediates Negative Feedback on Regulatory T Cell Function

(2010) A. Zanin-Zhorov et al.   SCIENCE

T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity

(2009) Natalia Martin-Orozco et al.   IMMUNITY

The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans

(2009) Kellie A. Charles et al.   JOURNAL OF CLINICAL INVESTIGATION

TNFR2-Deficient Memory CD8 T Cells Provide Superior Protection against Tumor Cell Growth

(2009) E. Y. Kim et al.   JOURNAL OF IMMUNOLOGY

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

(2008) J Askling et al.   ANNALS OF THE RHEUMATIC DISEASES

Low Levels of Tumor Necrosis Factor   Increase Tumor Growth by Inducing an Endothelial Phenotype of Monocytes Recruited to the Tumor Site

(2008) B. Li et al.   CANCER RESEARCH

TGF-β: A Master of All T Cell Trades

(2008) Ming O. Li et al.   CELL

Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells

(2008) Clare A. Notley et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis

(2008) Allison L Smitten et al.   ARTHRITIS RESEARCH & THERAPY

TNF-mediated inflammatory disease

(2007) JR Bradley   JOURNAL OF PATHOLOGY